The first fabilavir generic in China was approved for marketing

Novel coronavirus pneumonia was published in February 17, 2020 / medical information As of February 16th, 70548 cases were confirmed nationwide The first case in China and second cases of new crown pneumonia obtained by autopsy were completed The antiviral effect was not obvious and Lopinavir and Ritonavir Tablets was not recommended anymore Daily fresh medicine news, speed reading club and you pay attention to! As of 24:00 on February 16, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 57934 confirmed cases (including 10644 severe cases), 10844 cured and discharged cases, 1770 dead cases, 70548 confirmed cases and 7264 suspected cases There were 546016 close contacts and 150539 close contacts still under medical observation (official website of National Health Commission) 16 novel coronavirus pneumonia novel coronavirus pneumonia novel coronavirus pneumonia novel coronavirus pneumonia was first completed in second cases The pathology of new crown pneumonia obtained by anatomy was helpful to explore the clinical pathological changes and disease mechanism of new crown pneumonia patients, and can fundamentally explore the pathogenicity and lethality of the new crown pneumonia, and provide the basis for future clinical treatment of critically ill patients (Xinhua News Agency) 17, the national novel coronavirus infection pneumonia expert group member, Zhongshan Hospital Affiliated to Fudan University infectious disease director Hu Bijie told the Global Times: early use of anti AIDS drugs Lopinavir and Ritonavir Tablets, some patients will have diarrhea and other side effects, its clinical effect against the virus is not obvious, is no longer recommended Use (medicine cube) Novel coronavirus pneumonia is China's novel coronavirus pneumonia epidemic prevention and control medical device list, which is published recently by the China Medical Equipment Association (X) It also published the first catalogue of the new medical equipment for the prevention and control of new crown pneumonia The catalogue includes 27 medical devices, including heavy monitors, invasive ventilator, defibrillator, patient monitor, infusion pump, digital X ray, and many well-known domestic enterprises In columns (cypress blue instrument) Recently, Haizheng pharmaceutical's fabiravir tablet was officially approved by the State Food and Drug Administration for drug registration According to the data of the State Food and drug administration, the imitative drug of Haizheng Pharmaceutical Co., Ltd fapiravir has been approved for marketing, and the indication is for the treatment of new or recurrent influenza in adults (only used when other anti influenza drugs are ineffective or ineffective) (cypress blue) Cologne Pharmaceutical Co., Ltd announced the research progress of four anti new coronavirus drugs, including one innovative polypeptide drug and three generic drugs, involving innovative polypeptides and inhalation preparations for prevention of new virus, lopinavir / ritonavir tablets and oseltamivir capsules (Kelun pharmaceutical announcement) On July 17, capecitabine tablets of Hengrui medicine passed the consistency evaluation of quality and efficacy of generic drugs It is reported that capecitabine is a precursor of 5- fluorouracil, which can be transformed into 5- fluorouracil in vivo through the high concentration of thymidine phosphorylase in tumor tissue, inhibit the synthesis of DNA and RNA, and play an anti-tumor role (Sina Medical News) Hengrui pharmaceutical announced that its subsidiary, Ruishi biomedical, recently received the clinical trial notice of shr0302 tablets approved and issued by the State Food and drug administration Shr0302 is a small molecule selective inhibitor of Jak1 kinase, which is intended to be used in the treatment of alopecia areata (Sina Medical News) On the 15th, BMS released 5-year follow-up data of the phase III checkmate-025 study in patients with advanced or metastatic renal cell carcinoma treated with opdivo Checkmate-025 is an open label, randomized, phase III clinical trial designed to evaluate the efficacy and safety of opdivo versus everolimus in patients with advanced or metastatic RCC who have previously received antiangiogenic therapy (medicine cube) The clinical application of ibi362 for injection filed by Cinda biology was accepted by CDE on May 15 Developed by Lilly, ibi362 is a potential best in class glucagon like peptide-1 and glucagon receptor double agonist in the middle stage of clinical development New Zealand Green, a recombinant human for injection, failed to get approval from the State Food and drug administration due to lack of available research data, Zesheng technology announced Tuesday It is reported that the reasons for the lack of data are mainly clinical, pharmaceutical, pharmacological and toxicological aspects (medicine cube) Recently, Astellas and Seattle genetics published the latest results of padcev combined with keytruda in the treatment of stage Ib / II clinical trial ev-103 of locally advanced or metastatic urothelial carcinoma The results showed that after a median follow-up of 11.5 months in 45 patients, padcev + keytruda combination therapy reached the therapeutic safety index (Sina Medical News) Recently, a single arm phase II study (nct03534492) published at the 2020 American Society of clinical oncology urogenital cancer symposium (ASCO-GU 2020) held in San Francisco showed that the combination of AstraZeneca's anti PD-L1 therapy, imfinzi, and targeted anticancer drug lynparza showed strong efficacy in the new adjuvant treatment of muscle invasive bladder cancer: the pathological complete remission rate reached 50% (Biovalley)